Supernus Pharmaceuticals Inc  

(Public, NASDAQ:SUPN)   Watch this stock  
Find more results for SUPN
+0.65 (3.07%)
Dec 2 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 20.70 - 21.80
52 week 9.51 - 26.84
Open 21.25
Vol / Avg. 0.00/573,464.00
Mkt cap 1.11B
P/E 42.74
Div/yield     -
EPS 0.51
Shares 49.51M
Beta 1.86
Inst. own 93%
Dec 1, 2016
Q3 2016 Supernus Pharmaceuticals Inc Earnings Release (Estimated)
Nov 29, 2016
Supernus Pharmaceuticals Inc at Piper Jaffray Healthcare Conference
Nov 17, 2016
Supernus Pharmaceuticals Inc at Jefferies Healthcare Conference
Nov 15, 2016
Supernus Pharmaceuticals Inc at Stifel Healthcare Conference
Nov 14, 2016
Supernus Pharmaceuticals Inc 3Q 2016 Business Update Conference Call
Oct 11, 2016
Supernus Pharmaceuticals conference call to discuss SPN-812 Phase IIb Topline Results - Webcast
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '16) 2015
Net profit margin 19.87% 9.70%
Operating margin 20.71% 10.61%
EBITD margin - 12.87%
Return on average assets 19.45% 8.60%
Return on average equity 29.86% 14.74%
Employees 344 -
CDP Score - -


1550 E Gude Dr
ROCKVILLE, MD 20850-1339
United States - Map
+1-301-8382500 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company offers products for the treatment of epilepsy, which include extended-release oxcarbazepine (Oxtellar XR) and extended-release topiramate (Trokendi XR). It develops multiple product candidates in psychiatry for the treatment of Impulsive Aggression (IA) and attention deficit hyperactivity disorder (ADHD). Its psychiatry product candidates include SPN-810 (molindone hydrochloride) and SPN-812 (viloxazine hydrochloride). It is also developing SPN-810 as a treatment for IA in patients who have ADHD and SPN-812 for the treatment of ADHD. It is developing SPN-809 (viloxazine hydrochloride) for the treatment of depression. It markets its products in the United States through its own specialty sales force and has collaborations with other pharmaceutical companies to license its products outside the United States.

Officers and directors

Charles W. Newhall III Independent Chairman of the Board
Age: 70
Bio & Compensation  - Reuters
Jack A. Khattar President, Chief Executive Officer, Secretary, Director
Age: 53
Bio & Compensation  - Reuters
Gregory S. Patrick Chief Financial Officer, Vice President
Age: 58
Bio & Compensation  - Reuters
Stefan K.F. Schwabe M.D., Ph.D. Executive Vice-President - Research & Development, Chief Medical Officer
Age: 63
Bio & Compensation  - Reuters
Padmanabh P. Bhatt Ph.D., Senior Vice President- Intellectual Property, Chief Scientific Officer
Age: 58
Bio & Compensation  - Reuters
Victor Vaughn Senior Vice President - Sales
Age: 57
Bio & Compensation  - Reuters
Georges Gemayel Ph.D. Independent Director
Age: 55
Bio & Compensation  - Reuters
Frederick M. Hudson CPA Independent Director
Age: 69
Bio & Compensation  - Reuters
William A. Nuerge Independent Director
Age: 62
Bio & Compensation  - Reuters
John M. Siebert Ph.D. Independent Director
Age: 75
Bio & Compensation  - Reuters